Pipeline Overview*
Pipeline Overview*
| Drug** | Indication | Pre-clinical | Phase 1/2 | Phase 3 | Marketed | |
|---|---|---|---|---|---|---|
| TALICIA® (RHB-105) | H. pylori infections | Two positive US Phase 3 studies; NDA submission planned |
||||
| RHB-104 | Crohn's disease | Positive top-line results from Phase 3 MAP US study |
||||
| RHB-204 | NTM infections | Pivotal Phase 3 study planned |
||||
| BEKINDA® (RHB-102) |
Gastroenteritis & gastritis | Positive results from Phase 3 U.S. study |
||||
| IBS-D | Positive results from Phase 2 U.S. study |
|||||
| RHB-106 | Bowel cleanser |  WW rights licensed to Salix Pharmaceuticals |
||||
| YELIVA® (ABC294640) | Multiple indications | Cholangiocarcinoma and other indications |
||||
| RHB-107 (MESUPRON) | Oncology/GI | Completed multiple clinical studies |
||||
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ** BEKINDA®, YELIVA® and TALICIA® are proposed tradenames which are subject to FDA review and approval
